(Q51777109)

English

Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

scientific article published on 15 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24126798

Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24126798

Helicobacter pylori

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Javier P Gisbert

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Adrian G McNicholl

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Miguel Fernandez-Bermejo

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Alicia C Marín

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Javier Molina-Infante

4

object named as

J Molina-Infante

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ángeles Perez-Aísa

2

object named as

A Perez-Aisa

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

I Modolell

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

F Bermejo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Castro-Fernández

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

R Antón

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

B Sacristán

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Cosme

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Y Harb

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Gonzalez-Barcenas

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Algaba

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

H. pylori Study Group of the Spanish Gastroenterology Association

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

15 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/24126798

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

59

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

383-389

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126798%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Rescue Therapy for Helicobacter pylori Infection 2012.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy]

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Heat shock proteins in pancreatic diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2900-X

21 January 2018

Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of two rescue therapies for Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin]

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effectiveness of quadruple salvage regimen for Helicobacter pylori infection according to the duration of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Re-treatment after Helicobacter pylori eradication failure.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is Culture Necessary before First-line Treatment for Helicobacter pylori Infection?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24126798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51777109&oldid=2211199211"